Potential nonclassical effects of vitamin D in transplant recipients

Transplantation

Volumn 89, Issue 2, 2010, Pages 131-137

  Courbebaisse, Marie ^a,b,c   Souberbielle, Jean Claude ^b,c,d   Thervet, Eric ^b,c,e  

^a HÔPITAL TENON   (France)

^b INSERM   (France)

^c UNIVERSITÉ PARIS DESCARTES   (France)

^d HÔPITAL NECKER ENFANTS MALADES   (France)

^e ASSISTANCE PUBLIQUE HÔPITAUX DE PARIS   (France)

Author keywords

Long term complications; Metabolism; Solid organ transplantation; Vitamine D

Indexed keywords

BACTERICIDE; CALCITRIOL; CALCIUM; COLECALCIFEROL; CYTOKINE; METALLOPROTEINASE; PARATHYROID HORMONE; VITAMIN D;

APOPTOSIS; AUTOCRINE EFFECT; AUTOIMMUNE DISEASE; CALCIUM BLOOD LEVEL; CANCER RISK; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CELL DIFFERENTIATION; CELL PROLIFERATION; CYTOKINE PRODUCTION; GLYCEMIC CONTROL; GRAFT RECIPIENT; HUMAN; INFECTION; INFECTION RISK; INSULIN RELEASE; INSULIN RESISTANCE; MORTALITY; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; ORGAN TRANSPLANTATION; PARACRINE SIGNALING; PARATHYROID HORMONE BLOOD LEVEL; PLEIOTROPY; PRIORITY JOURNAL; RENAL PROTECTION; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; RENIN RELEASE; REVIEW; RISK REDUCTION; SECONDARY HYPERPARATHYROIDISM; VITAMIN D DEFICIENCY; VITAMIN D METABOLISM; VITAMIN SUPPLEMENTATION;

EID: 76749156322     PISSN: 00411337     EISSN: None     Source Type: Journal    
DOI: 10.1097/TP.0b013e3181c6910f     Document Type: Review

References (126)

1. Holick MF. Vitamin D deficiency. N Engl J Med 2007; 357: 266.
2. Dawson-Hughes B, Heaney RP, Holick MF, et al. Estimates of optimal vitamin D status. Osteoporos Int 2005; 16: 713.
3. Heaney RP. Vitamin D depletion and effective calcium absorption. J Bone Miner Res 2003; 18: 1342; authorreply 1343.
4. Bischoff-Ferrari HA, Giovannucci E, Willett WC, et al. Estimation of optimal serum concentrations of 25-hydroxyvitamin D for multiple health outcomes. Am J Clin Nutr 2006; 84: 18.
5. Vieth R, Chan PC, MacFarlane GD. Efficacy and safety of vitamin D3 intake exceeding the lowest observed adverse effect level. Am J Clin Nutr 2001; 73: 288.
6. Zittermann A. Vitamin D in preventive medicine: Are we ignoring the evidence? Br J Nutr 2003; 89: 552.
7. Binkley N, Krueger D, Cowgill CS, et al. Assay variation confounds the diagnosis of hypovitaminosis D: A call for standardization. J Clin Endocrinol Metab 2004; 89: 3152.
8. van der Wielen RP, Lowik MR, van den Berg H, et al. Serum vitamin D concentrations among elderly people in Europe. Lancet 1995; 346:207.
9. Tangpricha V, Pearce EN, Chen TC, et al. Vitamin D insufficiency among free-living healthy young adults. Am J Med 2002; 112: 659.
10. Querings K, Girndt M, Geisel J, et al. 25-hydroxyvitamin D deficiency in renal transplant recipients. J Clin Endocrinol Metab 2006; 91: 526.
11. Sadlier DM, Magee CC. Prevalence of 25(OH) vitamin D (calcidiol) deficiency at time of renal transplantation: A prospective study. Clin Transplant 2007; 21: 683.
12. Stavroulopoulos A, Cassidy MJ, Porter CJ, et al. Vitamin D status in renal transplant recipients. Am J Transplant 2007; 7: 2546.
13. Pascussi JM, Robert A, Nguyen M, et al. Possible involvement of pregnane X receptor-enhanced CYP24 expression in drug-induced osteomalacia. J Clin Invest 2005; 115: 177.
14. Akeno N, Matsunuma A, Maeda T, et al. Regulation of vitamin D-1alpha-hydroxylase and-24-hydroxylase expression by dexametha-sone in mouse kidney. J Endocrinol 2000; 164: 339.
15. Bhan I, Shah A, Holmes J, et al. Post-transplant hypophosphatemia: Tertiary 'Hyper-Phosphatoninism'? Kidney Int 2006; 70: 1486.
16. Pande S, Ritter CS, Rothstein M, et al. FGF-23 and sFRP-4 in chronic kidney disease and post-renal transplantation. Nephron Physiol 2006; 104: 23.
17. Saito H, Kusano K, Kinosaki M, et al. Human fibroblast growth fac-tor-23 mutants suppress Na+-dependent phosphate co-transport activity and 1alpha, 25-dihydroxyvitamin D3 production. J Biol Chem 2003; 278: 2206.
18. Courbebaisse M, Thervet E, Souberbielle JC, et al. Effects of vitamin D supplementation on the calcium-phosphate balance in renal transplant patients. Kidney Int 2009; 75: 646.
19. Montori VM, Basu A, Erwin PJ, et al. Posttransplantation diabetes: A systematic review of the literature. Diabetes Care 2002; 25: 583.
20. Pittas AG, Lau J, Hu FB, et al. The role of vitamin D and calcium in type 2 diabetes. A systematic review and meta-analysis. J Clin Endocrinol Metab 2007; 92: 2017.
21. Johnson JA, Grande JP, Roche PC, et al. Immunohistochemical localization of the 1, 25(OH)2D3 receptor and calbindin D28k in human and rat pancreas. Am J Physiol 1994; 267(3 pt 1): E356.
22. Bland R, Markovic D, Hills CE, et al. Expression of 25-hydroxyvitamin D3-1alpha-hydroxylase in pancreatic islets. J Steroid Biochem Mol Biol 2004; 89-90: 121.
23. Maestro B, DavilaN, CarranzaMC, et al. Identification of a Vitamin D response element in the human insulin receptor gene promoter. J Steroid Biochem Mol Biol 2003; 84: 223.
24. Bourlon PM, Billaudel B, Faure-Dussert A. Influence of vitamin D3 deficiency and 1, 25 dihydroxyvitamin D3 on de novo insulin biosynthesis in the islets of the rat endocrine pancreas. J Endocrinol 1999; 160: 87.
25. Norman AW, Frankel JB, Heldt AM, et al. Vitamin D deficiency inhibits pancreatic secretion of insulin. Science 1980; 209: 823.
26. Kadowaki S, Norman AW. Dietary vitamin D is essential for normal insulin secretion from the perfused rat pancreas. J Clin Invest 1984; 73: 759.
27. Tanaka Y, Seino Y, Ishida M, et al. Effect of vitamin D3 on the pancreatic secretion of insulin and somatostatin. Acta Endocrinol (Copenh) 1984; 105: 528.
28. Zeitz U, Weber K, Soegiarto DW, et al. Impaired insulin secretory capacity in mice lacking a functional vitamin D receptor. FASEB J 2003; 17: 509.
29. Cade C, Norman AW. Vitamin D3 improves impaired glucose tolerance and insulin secretion in the vitamin D-deficient rat in vivo. Endocrinology 1986; 119: 84.
30. Scragg R, Sowers M, Bell C.Serum 25-hydroxyvitaminD, diabetes, and ethnicityin the Third National Health and Nutrition Examination Survey. Diabetes Care 2004; 27: 2813.
31. Hypponen E, Power C. Vitamin D status and glucose homeostasis in the 1958 British birth cohort: The role of obesity. Diabetes Care 2006; 29: 2244.
32. Sun X, Zemel MB. Calcium and 1, 25-dihydroxyvitamin D3 regulation of adipokine expression. Obesity (Silver Spring) 2007; 15: 340.
33. Nagpal J, Pande JN, Bhartia A. A double-blind, randomized, placebo-controlled trial of the short-term effect of vitamin D3 supplementation on insulin sensitivity in apparently healthy, middle-aged, centrally obese men. Diabet Med 2009; 26: 19.
34. Sarnak MJ, Levey AS, Schoolwerth AC, et al. Kidney disease as a risk factor for development of cardiovascular disease: A statement from the American Heart Association Councils on Kidney in Cardiovascular Disease, High Blood Pressure Research, Clinical Cardiology, and Epidemiology and Prevention. Hypertension 2003; 42: 1050.
35. London GM, Guerin AP, Verbeke FH, et al. Mineral metabolism and arterial functions in end-stage renal disease: Potential role of 25-hydroxyvitamin D deficiency. J Am Soc Nephrol 2007; 18: 613.
36. Wang TJ, Pencina MJ, Booth SL, et al. Vitamin D deficiency and risk of cardiovascular disease. Circulation 2008; 117: 503.
37. Giovannucci E, Liu Y, Hollis BW, et al. 25-hydroxyvitamin D and risk of myocardial infarction in men: A prospective study. Arch Intern Med 2008; 168: 1174.
38. Pilz S, Marz W, Wellnitz B, et al. Association of vitamin D deficiency with heart failure and sudden cardiac death in a large cross-sectional study of patients referred for coronary angiography. J Clin Endocrinol Metab 2008; 93: 3927.
39. PilzS, DobnigH, NijpelsG, et al. Vitamin D and mortalityinolder men and women. Clin Endocrinol (Oxf) 2009; 71: 666.
40. Dobnig H, Pilz S, Scharnagl H, et al. Independent association of low serum 25-hydroxyvitamin d and 1, 25-dihydroxyvitamin d levels with all-cause and cardiovascular mortality. Arch Intern Med 2008; 168: 1340.
41. Zittermann A, Schleithoff SS, Koerfer R. Putting cardiovascular disease and vitamin D insufficiency into perspective. Br J Nutr 2005; 94: 483.
42. Wu J, Garami M, Cheng T, et al. 1, 25(OH)2 vitamin D3, and retinoic acid antagonize endothelin-stimulated hypertrophy of neonatal rat cardiac myocytes. J Clin Invest 1996; 97: 1577.
43. O'Connell TD, Berry JE, Jarvis AK, et al. 1, 25-Dihydroxyvitamin D3 regulation of cardiac myocyte proliferation and hypertrophy. Am J Physiol 1997; 272(4 pt 2): H1751.
44. Nibbelink KA, Tishkoff DX, Hershey SD, et al. 1, 25(OH)2-vitamin D3 actions on cell proliferation, size, gene expression, and receptor localization, in the HL-1 cardiac myocyte. J Steroid Biochem Mol Biol 2007; 103: 533.
45. Cardus A, Parisi E, Gallego C, et al. 1, 25-Dihydroxyvitamin D3 stimulates vascular smooth muscle cell proliferation through a VEGF-mediated pathway. Kidney Int 2006; 69: 1377.
46. Green JJ, Robinson DA, Wilson GE, et al. Calcitriol modulation of cardiac contractile performance via protein kinase C. J Mol Cell Cardiol 2006; 41: 350.
47. Tishkoff DX, Nibbelink KA, Holmberg KH, et al. Functional vitamin D receptor (VDR) in the t-tubules of cardiac myocytes: VDR knockout cardiomyocyte contractility. Endocrinology 2008; 149: 558.
48. Bouillon R, Carmeliet G, Verlinden L, et al. Vitamin D and human health: Lessons from vitamin D receptor null mice. Endocr Rev 2008; 29: 726.
49. Qiao G, Kong J, Uskokovic M, et al. Analogs of 1alpha, 25-dihydroxyvitamin D(3) as novel inhibitors of renin biosynthesis. J Steroid Biochem Mol Biol 2005; 96: 59.
50. Sigmund CD. Regulation of renin expression and blood pressure by vitamin D(3). J Clin Invest 2002; 110: 155.
51. Zhou C, Lu F, Cao K, et al. Calcium-independent and 1, 25(OH)2D3-dependent regulation of the renin-angiotensin system in 1alpha-hydroxylase knockout mice. Kidney Int 2008; 74: 170.
52. Nakagawa K, Sasaki Y, Kato S, et al. 22-Oxa-1alpha, 25-dihydroxyvitamin D3 inhibits metastasis and angiogenesis in lung cancer. Carcinogenesis 2005; 26: 1044.
53. Basalyga DM, Simionescu DT, Xiong W, et al. Elastin degradation and calcification in an abdominal aorta injury model: Role of matrix met-alloproteinases. Circulation 2004; 110: 3480.
54. Schleithoff SS, Zittermann A, Tenderich G, et al. Vitamin D supplementation improves cytokine profiles in patients with congestive heart failure: A double-blind, randomized, placebo-controlled trial. Am J Clin Nutr 2006; 83: 754.
55. Tarcin O, Yavuz DG, Ozben B, et al. Effect of vitamin D deficiency and replacement on endothelial function in asymptomatic subjects. J Clin Endocrinol Metab 2009; 94: 4023.
56. Witham MD, Nadir MA, Struthers AD. Effect of vitamin D on blood pressure: A systematic review and meta-analysis. J Hypertens 2009; 27: 1948.
57. Zittermann A, Schleithoff SS, Koerfer R. Vitamin D and vascular calcification. Curr Opin Lipidol 2007; 18: 41.
58. Kasiske BL, Snyder JJ, Gilbertson DT, et al. Cancer after kidney transplantation in the United States. Am J Transplant 2004; 4: 905.
59. Garland CF, Garland FC. Do sunlight and vitamin D reduce the likelihood of colon cancer? Int J Epidemiol 1980; 9: 227.
60. Giovannucci E. Epidemiological evidence for vitamin D and colorectal cancer. J Bone Miner Res 2007; 22(suppl 2): V81.
61. Garland CF, Gorham ED, Mohr SB, et al. Vitamin D and prevention of breast cancer: Pooled analysis. J Steroid Biochem Mol Biol 2007; 103: 708.
62. Ahonen MH, Tenkanen L, Teppo L, et al. Prostate cancer risk and prediagnostic serum 25-hydroxyvitamin D levels (Finland). Cancer Causes Control 2000; 11: 847.
63. Tworoger SS, Lee IM, Buring JE, et al. Plasma 25-hydroxyvitamin D and 1, 25-dihydroxyvitaminD and risk ofincident ovarian cancer.Cancer Epidemiol Biomarkers Prev 2007; 16: 783.
64. Soni LK, Hou L, Gapstur SM, et al. Sun exposure and non-Hodgkin lymphoma: A population-based, case-control study. Eur JCancer2007; 43: 2388.
65. Polesel J, Talamini R, Montella M, et al. Linoleic acid, vitamin D and other nutrient intakes in the risk of non-Hodgkin lymphoma: An Italian case-control study. Ann Oncol 2006; 17: 713.
66. Tretli S, Hernes E, Berg JP, et al. Association between serum 25(OH)D and death from prostate cancer. Br J Cancer 2009; 100: 450.
67. Ducloux D, Courivaud C, Bamoulid J, et al. Pretransplant serum vitamin D levels and risk of cancer after renal transplantation. Transplantation 2008; 85: 1755.
68. Tuohimaa P, Tenkanen L, Ahonen M, et al. Both high and low levels of blood vitamin D are associated with a higher prostate cancer risk: A longitudinal, nested case-control study in the Nordic countries. Int J Cancer 2004; 108: 104.
69. Ellison TI, Smith MK, Gilliam AC, et al. Inactivation of the vitamin D receptor enhances susceptibility of murine skin to UV-induced tumor-igenesis. J Invest Dermatol 2008; 128: 2508.
70. Liu M, Lee MH, Cohen M, et al. Transcriptional activation of the Cdk inhibitor p21 by vitamin D3 leads to the induced differentiation of the myelomonocytic cell line U937. Genes Dev 1996; 10: 142.
71. Diaz GD, Paraskeva C, Thomas MG, et al. Apoptosis is induced by the active metabolite of vitamin D3 and its analogue EB1089 in colorectal adenoma and carcinoma cells: Possible implications for prevention and therapy. Cancer Res 2000; 60: 2304.
72. Tangpricha V, Flanagan JN, Whitlatch LW, et al. 25-hydroxyvitamin D-1alpha-hydroxylase in normal and malignant colon tissue. Lancet 2001; 357: 1673.
73. Mantell DJ, Owens PE, Bundred NJ, et al. 1 alpha, 25-dihydroxyvitamin D(3) inhibits angiogenesis in vitro and in vivo. Circ Res 2000; 87: 214.
74. Fleet JC. Molecular actions of vitamin D contributing to cancer prevention. Mol Aspects Med 2008; 29: 388.
75. Wactawski-Wende J, Kotchen JM, Anderson GL, et al. Calcium plus vitamin D supplementation and the risk of colorectal cancer. N Engl J Med 2006; 354: 684.
76. Lappe JM, Travers-Gustafson D, Davies KM, et al. Vitamin D and calcium supplementation reduces cancer risk: Results of a randomized trial. Am J Clin Nutr 2007; 85: 1586.
77. Fishman JA. Infection in solid-organ transplant recipients. N Engl J Med 2007; 357: 2601.
78. Cannell JJ, Vieth R, Umhau JC, et al. Epidemic influenza and vitamin D. Epidemiol Infect 2006; 134: 1129.
79. Mora JR, Iwata M, von Andrian UH. Vitamin effects on the immune system: Vitamins A and D take centre stage. Nat Rev Immunol 2008; 8: 685.
80. Liu PT, Stenger S, Li H, et al. Toll-like receptor triggering of a vitamin D-mediated human antimicrobial response. Science 2006; 311: 1770.
81. Ohta M, Okabe T, Ozawa K, et al. 1 alpha, 25-Dihydroxyvitamin D3 (calcitriol) stimulates proliferation of human circulating monocytes in vitro. FEBS Lett 1985; 185: 9.
82. Bhalla AK, Amento EP, Krane SM. Differential effects of 1, 25-dihydroxyvitamin D3 on human lymphocytes and monocyte/macro-phages: Inhibition of interleukin-2 and augmentation of interleukin-1 production. Cell Immunol 1986; 98: 311.
83. Aloia JF, Li-Ng M. Re: Epidemic influenza and vitamin D. Epidemiol Infect 2007; 135: 1095.
84. StPeter WL, Li S, LiuJ, et al. Effects of monthly dose and regular dosing of intravenous active vitamin D use on mortality among patients undergoing hemodialysis. Pharmacotherapy 2009; 29: 154.
85. Tanaci N, Karakose H, Guvener N, et al. Influence of 1, 25-dihydroxyvita-min D3 as an immunomodulator in renal transplant recipients: A retrospective cohort study. Transplant Proc 2003; 35: 2885.
86. Sezer S, Uyar M, Arat Z, et al. Potential effects of 1, 25-dihydroxyvitamin D3 in renal transplant recipients. Transplant Proc 2005; 37: 3109.
87. O'Herrin JK, Hullett DA, Heisey DM, et al. A retrospective evaluation of 1, 25-dihydroxyvitamin D(3) and its potential effects on renal allo-graft function. Am J Nephrol 2002; 22: 515.
88. Rigby WF, Stacy T, Fanger MW. Inhibition of T lymphocyte mitogen-esis by 1, 25-dihydroxyvitamin D3 (calcitriol). J Clin Invest 1984; 74: 1451.
89. Lemire JM, Adams JS, Kermani-Arab V, et al. 1, 25-Dihydroxyvitamin D3 suppresses human T helper/inducer lymphocyte activity in vitro. J Immunol 1985; 134: 3032.
90. Reichel H, Koeffler HP, Tobler A, Norman AW. 1 alpha, 25-Dihydroxyvitamin D3 inhibits gamma-interferon synthesis by normal human peripheral blood lymphocytes.Proc Natl Acad Sci USA1987; 84: 3385.
91. Rigby WF, Yirinec B, Oldershaw RL, et al. Comparison of the effects of 1, 25-dihydroxyvitamin D3 on T lymphocyte subpopulations. Eur J Immunol 1987; 17: 563.
92. Veldman CM, Cantorna MT, DeLuca HF. Expression of 1, 25-dihydroxyvitamin D(3) receptor in the immune system. Arch Biochem Biophys 2000; 374: 334.
93. Chen S, Sims GP, Chen XX, et al. Modulatory effects of 1, 25-dihydroxyvitaminD3 onhuman B cell differentiation.J Immunol 2007; 179: 1634.
94. van Etten E, MathieuC. Immunoregulationby1, 25-dihydroxyvitamin D3: Basic concepts. J Steroid Biochem Mol Biol 2005; 97: 93.
95. Fritsche J, Mondal K, Ehrnsperger A, et al. Regulation of 25-hydroxyvitamin D3-1 alpha-hydroxylase and production of 1 alpha, 25-dihydroxyvita-min D3 by human dendritic cells. Blood 2003; 102: 3314.
96. Penna G, Adorini L. 1 Alpha, 25-dihydroxyvitamin D3 inhibits differentiation, maturation, activation, and survival of dendritic cells leading to impaired alloreactive T cell activation. J Immunol 2000; 164: 2405.
97. Griffin MD, Lutz W, Phan VA, et al. Dendritic cell modulation by 1alpha, 25 dihydroxyvitamin D3 and its analogs: A vitamin D receptor-dependent pathway that promotes a persistent state of immaturity in vitro and in vivo. Proc Natl Acad Sci USA 2001; 98: 6800.
98. Chen W. The role of plasmacytoid dendritic cells in immunity and tolerance. Curr Opin Organ Transplant 2005; 10: 181.
99. Adorini L, Amuchastegui S, Daniel KC. Prevention of chronic allograft rejection by vitamin D receptor agonists. Immunol Lett 2005; 100: 34.
100. Lemire JM, Archer DC, Khulkarni A, et al. Prolongation of the survival of murine cardiac allografts by the vitamin D3 analogue 1, 25-dihy-droxy-delta 16-cholecalciferol. Transplantation 1992; 54: 762.
101. Zhang AB, Zheng SS, Jia CK, et al. Effect of 1, 25-dihydroxyvitamin D3 on preventing allograft from acute rejection following rat orthotopic liver transplantation. World J Gastroenterol 2003; 9: 1067.
102. Casteels K, Waer M, Laureys J, et al. Prevention of autoimmune destruction of syngeneic islet grafts in spontaneously diabetic nonobese diabetic mice by a combination of a vitamin D3 analog and cyclospor-ine. Transplantation 1998; 65: 1225.
103. Hullett DA, Laeseke PF, Malin G, et al. Prevention of chronic allograft nephropathy with vitamin D. Transpl Int 2005; 18: 1175.
104. Amuchastegui S, Daniel KC, Adorini L. Inhibition of acute and chronic allograft rejection in mouse models by BXL-628, a nonhypercalcemic vitamin D receptor agonist. Transplantation 2005; 80: 81.
105. Cantorna MT, Hullett DA, RedaelliC, et al. 1, 25-Dihydroxyvitamin D3 prolongs graft survival without compromising host resistance to infection or bone mineral density. Transplantation 1998; 66: 828.
106. Agarwal R, Acharya M, Tian J, et al. Antiproteinuric effect of oral pari-calcitol in chronic kidney disease. Kidney Int 2005; 68: 2823.
107. Li YC. Renoprotective effects of vitamin D analogs. Kidney Int 2009. In press.
108. de Boer IH, Ioannou GN, Kestenbaum B, et al. 25-Hydroxyvitamin D levels and albuminuria in the Third National Health and Nutrition Examination Survey (NHANES III). Am J Kidney Dis 2007; 50: 69.
109. Ravani P, Malberti F, Tripepi G, et al. Vitamin D levels and patient outcome in chronic kidney disease. Kidney Int 2009; 75: 88.
110. Brewster UC, Perazella MA. The renin-angiotensin-aldosterone system and the kidney: Effects on kidney disease. Am J Med 2004; 116: 263.
111. Sun J, Kong J, Duan Y, et al. Increased NF-kappaB activityinfibroblasts lacking the vitamin D receptor. Am J Physiol Endocrinol Metab 2006; 291: E315.
112. Guijarro C, Egido J. Transcription factor-kappa B (NF-kappa B) and renal disease. Kidney Int 2001; 59: 415.
113. Tan X, Li Y, Liu Y. Paricalcitol attenuates renal interstitial fibrosis in obstructive nephropathy. J Am Soc Nephrol 2006; 17: 3382.
114. Schwarz U, Amann K, Orth SR, et al. Effect of 1, 25 (OH)2 vitamin D3 on glomerulosclerosis in subtotally nephrectomized rats. Kidney Int 1998; 53: 1696.
115. Kuhlmann A, Haas CS, Gross ML, et al. 1, 25-Dihydroxyvitamin D3 decreases podocyte loss and podocyte hypertrophy in the subtotally nephrectomized rat. Am J Physiol Renal Physiol 2004; 286: F526.
116. Freundlich M, Quiroz Y, Zhang Z, et al. Suppression of renin-angio-tensin gene expression in the kidney by paricalcitol. Kidney Int 2008; 74: 1394.
117. Zhang Z, Sun L, Wang Y, et al. Renoprotective role of the vitamin D receptor in diabetic nephropathy. Kidney Int 2008; 73: 163.
118. Alborzi P, Patel NA, Peterson C, et al. Paricalcitol reduces albuminuria and inflammation in chronic kidney disease: A randomized double-blind pilot trial. Hypertension 2008; 52: 249.
119. AutierP, GandiniS. VitaminD supplementation and total mortality: A meta-analysis of randomized controlled trials. Arch Intern Med 2007; 167: 1730.
120. Naves-Diaz M, Alvarez-Hernandez D, Passlick-Deetjen J, et al. Oral active vitamin D is associated with improved survival in hemodialysis patients. Kidney Int 2008; 74: 1070.
121. Teng M, Wolf M, Ofsthun MN, et al. Activated injectable vitamin D and hemodialysis survival: A historical cohort study. J Am Soc Nephrol 2005; 16: 1115.
122. Tentori F, Hunt WC, Stidley CA, et al. Mortality risk among hemodi-alysis patients receiving different vitamin D analogs. Kidney Int 2006; 70: 1858.
123. Kovesdy CP, Ahmadzadeh S, Anderson JE, et al. Association of activated vitamin D treatment and mortality in chronic kidney disease. Arch Intern Med 2008; 168: 397.
124. Shoben AB, Rudser KD, de Boer IH, et al. Association of oral calcitriol with improved survival in nondialyzed CKD. J Am Soc Nephrol 2008; 19: 1613.
125. Teng M, Wolf M, Lowrie E, et al. Survival of patients undergoing he-modialysis with paricalcitol or calcitriol therapy. N Engl J Med 2003; 349: 446.
126. Zittermann A, Schleithoff SS, Gotting C, et al. Calcitriol deficiency and 1-year mortality in cardiac transplant recipients. Transplantation 2009; 87: 118.